Traditionally, every two years, HAE International (HAEi) hosted the HAE Global Conference where patients, caregivers, member organizations, pharmaceutical companies and physicians joined together to learn and connect. This year, after a COVID-caused delay, and the
Canadian Blood Services (CBS) Announces the Results of the Request for Proposals (RFP) for Plasma-Derived Plasma Protein and Related Products (PPRP). Through their formulary, CBS provides many patients across Canada, including patients with HAE, with
To celebrate hae day :-) over 5,000 people around the world contributed their steps to the 2022 Virtual Global Walk. Thank you to the 911 Canadians who added their steps to help make this awareness campaign
We are thrilled to share BioCryst Pharmaceutical's big announcement: Health Canada has approved their oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of HAE attacks in patients 12 years and older. Please CLICK HERE for
Héma-Québec, the organization in Quebec that manages blood and biological products, has awarded a two-year tender for TAKHZYRO® (lanadelumab injection), as the sole option for prophylaxis subcutaneous (SC) treatment for Type I/II HAE patients.
HAE International is offering free, online advocacy courses. This extremely comprehensive program is designed to support people with HAE in everyday life. The courses are delivered in small manageable chunks and can be accessed at any time, from anywhere
Please join us on Saturday November 20th from 1:00-3:00pm ET for our next Update! Details can also be found on our Upcoming Events page.
We hope you can join us for our 2021 AGM. Please check your inbox for the invitation and links to register. Please check your spam box if you do not receive our invitation - unfortunately
Please mark your calendars! HAE Canada is hosting a Virtual Patient Information Update on November 20th at 1:00pm ET. Speakers, topics and other important details will be shared soon - we hope to see you
Lanadelumab (TAKHZYRO), a treatment to routinely prevent attacks in patients with HAE Type I or II who are 12 years old and up, was recently added to Nova Scotia's drug formulary. To access this treatment,